全文获取类型
收费全文 | 717篇 |
免费 | 40篇 |
国内免费 | 6篇 |
专业分类
儿科学 | 13篇 |
妇产科学 | 12篇 |
基础医学 | 78篇 |
口腔科学 | 6篇 |
临床医学 | 56篇 |
内科学 | 234篇 |
皮肤病学 | 4篇 |
神经病学 | 44篇 |
特种医学 | 28篇 |
外科学 | 90篇 |
综合类 | 3篇 |
预防医学 | 27篇 |
眼科学 | 11篇 |
药学 | 70篇 |
肿瘤学 | 87篇 |
出版年
2023年 | 4篇 |
2022年 | 3篇 |
2021年 | 21篇 |
2020年 | 9篇 |
2019年 | 17篇 |
2018年 | 18篇 |
2017年 | 16篇 |
2016年 | 22篇 |
2015年 | 16篇 |
2014年 | 28篇 |
2013年 | 38篇 |
2012年 | 58篇 |
2011年 | 67篇 |
2010年 | 27篇 |
2009年 | 29篇 |
2008年 | 34篇 |
2007年 | 29篇 |
2006年 | 37篇 |
2005年 | 34篇 |
2004年 | 41篇 |
2003年 | 28篇 |
2002年 | 45篇 |
2001年 | 13篇 |
2000年 | 12篇 |
1999年 | 12篇 |
1998年 | 10篇 |
1997年 | 8篇 |
1996年 | 7篇 |
1995年 | 4篇 |
1994年 | 3篇 |
1993年 | 6篇 |
1992年 | 10篇 |
1991年 | 5篇 |
1990年 | 7篇 |
1989年 | 3篇 |
1988年 | 3篇 |
1987年 | 10篇 |
1986年 | 7篇 |
1985年 | 2篇 |
1984年 | 6篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1976年 | 2篇 |
1975年 | 2篇 |
1973年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有763条查询结果,搜索用时 31 毫秒
11.
12.
N Marziliano PA Merlini G Vignati F Orsini V Motta L Bandiera M Intrieri S Veronese 《Neonatology》2012,102(4):254-258
Hypertrophic cardiomyopathy (HCM) is a familial, genetically determined, primary cardiomyopathy caused by mutations in genes coding for proteins of the sarcomere, or, less frequently, genes involved in storage diseases. In pediatric settings, pure HCM has an estimated incidence of 4.7 per million children. The disease is often sub-clinical and goes unrecognized mainly because most patients with HCM have only mild symptoms, if any. However, sudden cardiac death, the most dramatic clinical occurrence and the primary concern for patients and physicians alike, may be the first manifestation of the disease. We describe a case of compound heterozygosity in the MYBPC3 gene (p.Glu258Lys and IVS25-1G>A) associated with biventricular hypertrophy, atrial enlargement and subsequent neonatal death 33 days postpartum. Other studies have reported compound and/or double heterozygosis in the same or different sarcomeric genes during childhood and adulthood, and neonatal presentations have also been described. Our observations show that the combination of a missense (p.Glu258Lys) and a splice-site mutation (IVS25-1G>A) profoundly affects the clinical course. In families in which parental mutations are known, preimplantation (where ethically and legally feasible) or prenatal genetic screening should be adopted because: (1) neonatal HCM in genetic heterozygosity is potentially lethal and (2) heart disease is the most common developmental malformation and the leading cause of neonatal mortality and morbidity. 相似文献
13.
Annals of Surgical Oncology - 相似文献
14.
15.
16.
The effects of rifampicin treatment (10 mg.kg-1.day-1) on pruritus and cholestasis were evaluated in 16 patients with primary biliary cirrhosis and pruritus followed up for 2-24 months. Assessment of pruritus severity, liver tests, aminopyrine breath test, and bile acids was done at 2 weeks and every 3 months after the beginning of the study. Two patients (12.5%) were withdrawn after 2 months of treatment because they had hepatitis caused by rifampicin. Four patients were withdrawn after 4 months because of liver transplantation (3 cases) and the development of leg edema associated with administration of rifampicin. The remaining 10 patients received therapy for 14.4 +/- 0.7 months and did not experience side effects. Pruritus improved in all patients and disappeared in 11 patients (79%) after 3 months of treatment. Moreover, all patients followed up for more than 1 year were free of pruritus. The alkaline phosphatase level decreased significantly, and the aminopyrine breath test results increased significantly after 2 weeks of treatment (P less than 0.001) and did not change thereafter. In the 9 patients treated for 15 months, alkaline phosphatase levels decreased to 63% of the basal levels and aminopyrine breath test results increased to 153% of baseline values. Transaminases, gamma-glutamyltransferase, and total bile salt levels decreased significantly after 2 weeks of treatment but returned to baseline after 3 months. No changes in bilirubin and cholesterol levels were observed. It is concluded that long-term rifampicin treatment is effective for relieving pruritus in primary biliary cirrhosis, but liver enzymes should be monitored to detect drug-induced hepatitis. 相似文献
17.
Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis 总被引:1,自引:0,他引:1
Piera Sivera Luigi Cesano Angelo Guerrasio Clara Camaschella Umberto Mazza 《British journal of haematology》1994,86(2):397-398
Summary We report a patient with agnogenic myeloid metaplasia associated with debilitating bone pain due to increased bone turnover and osteosclerosis. Treatment with etidronate at a dose of 6 mg/kg per day on alternate months resulted in a complete recovery of bone symptoms and normalization of metabolic parameters of bone turnover; unexpectedly, a sustained haematological improvement was also observed after several months of therapy, suggesting that bone marrow microenvironment improvement was able to restore a nearly normal haemopoiesis. We suggest that diphosphonate therapy may be of value in patients with AMM and increased bone turnover. 相似文献
18.
Pelizzaro Filippo Kitenge Maria Piera Cardin Romilda Ponzoni Alberto Cillo Umberto Vitale Alessandro Businello Gianluca Munari Giada Fassan Matteo Farinati Fabio 《Clinical and experimental medicine》2021,21(4):675-682
Clinical and Experimental Medicine - We aimed to explore the activation of monoacylglycerol lipase (MAGL)/cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) axis in hepatocellular carcinoma (HCC),... 相似文献
19.
20.
Guevara M Fernández-Esparrach G Alessandria C Torre A Terra C Montañà X Piera C Alvarez ML Jiménez W Ginès P Arroyo V 《Hepatology (Baltimore, Md.)》2004,40(3):646-651
Patients with cirrhosis are frequently submitted to radiological procedures that require the administration of contrast media. Contrast media is a well-known cause of renal failure, particularly in the presence of some predisposing conditions. However, it is not known whether cirrhosis constitutes a risk factor for contrast media-induced renal failure. The aim of this study was to assess the possible nephrotoxicity of contrast media in patients with cirrhosis. In a first protocol, renal function was evaluated with sensitive methods (glomerular filtration rate using iothalamate I 125 clearance and renal plasma flow using iodohippurate I 131 clearance) before and 48 hours after the administration of contrast media in 31 patients with cirrhosis (20 with ascites, 5 with renal failure). Solute-free water clearance, urine sodium, prostaglandins, and markers of tubular damage were also measured. The administration of contrast media was not associated with significant changes in renal function tests, neither in the whole group of patients nor in patients with ascites or renal failure. Urinary prostaglandin E2 and N-acetyl-beta-D-glucosaminidase increased significantly, but sodium and solute-free water excretion remained unchanged. In a second protocol, a different series of 60 patients with cirrhosis and renal failure were examined prospectively. No patient had renal failure due to contrast media. Only in 1 patient with septic shock was contrast media a possible contributing factor. In conclusion, the administration of contrast media is not associated with adverse effects on renal function in patients with cirrhosis. Cirrhosis does not appear to be a risk factor for the development of contrast media-induced nephrotoxicity. 相似文献